Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Stopped Study discontinued considering the limited clinical benefit combined with a higher than expected rate of known non-serious ophthalmological event.
Conditions
- Triple Negative Breast Cancer
Interventions
- DRUG: SAR566658 (ACT14884)
Sponsor
Sanofi